Agree. Focus should be on year to year quarter to quarter growth and full yearly growth. BKL has achieved phenomenal results. Confident they can grow NPAT by another 50% plus for 2017.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress